Welcome to our dedicated page for Rapt Therapeutics news (Ticker: RAPT), a resource for investors and traders seeking the latest updates and insights on Rapt Therapeutics stock.
RAPT Therapeutics, Inc. (Nasdaq: RAPT) is a clinical-stage immunology-based biopharmaceutical company, and its news flow reflects the progress and risks of drug development in inflammatory and immunological diseases. Company announcements routinely describe advances in its pipeline, particularly its anti-IgE monoclonal antibody program ozureprubart (formerly RPT904), as well as financial updates and investor outreach activities.
Visitors to this news page can review press releases on key clinical milestones, such as FDA clearance of an Investigational New Drug application, initiation of the prestIgE Phase 2b trial of ozureprubart in IgE-mediated food allergy, and positive topline data from a Phase 2 trial in chronic spontaneous urticaria conducted by partner Shanghai Jeyou Pharmaceutical Co., Ltd. RAPT’s news also highlights how these data compare to existing therapies like omalizumab in terms of dosing intervals and measured endpoints within the reported studies.
RAPT frequently reports quarterly financial results, detailing research and development and general and administrative expenses, net losses and cash, cash equivalents and marketable securities. News items also cover capital-raising events, such as the pricing and completion of underwritten public offerings of common stock, and the company’s estimates regarding how long its capital resources may fund operations based on current plans.
In addition, RAPT issues press releases about participation in healthcare and investor conferences, including major events hosted by firms such as J.P. Morgan, Wells Fargo, Guggenheim, Stifel, TD Cowen, Cantor and H.C. Wainwright. These updates indicate when management will present company overviews or fireside chats and how investors can access related webcasts or archived presentations.
For investors and observers following RAPT, this news feed provides a consolidated view of clinical trial developments, regulatory interactions, financial disclosures and corporate events that shape the company’s progress in developing therapies for inflammatory and immunological diseases.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
RAPT Therapeutics, Inc. (Nasdaq: RAPT), focused on immunology and oncology therapies, announced a poster presentation for FLX475, its lead oncology drug candidate, at the 2023 ASCO annual meeting scheduled for June 2-6, 2023. The poster titled "Clinical and Biological Activity of FLX475, an Oral CCR4 Antagonist, in Advanced Cancer" will be presented on June 3, 2023, from 8:00 a.m. to 11:00 a.m. ET. The abstract associated with the presentation will be released on May 25, 2023. RAPT is advancing two key drug candidates, RPT193 and FLX475, aimed at treating inflammatory diseases and cancer, respectively, showcasing their commitment to addressing significant unmet medical needs.
RAPT Therapeutics (Nasdaq: RAPT) has launched a global 14-week Phase 2a clinical trial to assess the safety and efficacy of RPT193, an oral therapy for patients with moderate-to-severe asthma. The double-blind, placebo-controlled study will involve around 100 patients with Type 2-high asthma. The trial follows promising results from a prior Phase 1b trial in atopic dermatitis. Primary endpoints include measuring the lack of asthma control, with patients transitioning to monotherapy in the final weeks. RPT193 targets the CCR4 receptor, potentially addressing significant unmet needs in asthma treatment.
RAPT Therapeutics reported its financial results for Q4 and the full year ending December 31, 2022, revealing a net loss of $23.0 million for Q4 and $83.8 million for the year. Research and development (R&D) expenses rose to $19.5 million in Q4 and $67.1 million for the year, primarily due to costs associated with lead programs RPT193 and FLX475. The company's cash position remains strong at $249.1 million, anticipated to last into mid-2025. RAPT plans to initiate a Phase 2a trial for RPT193 in asthma soon, with topline results for a related trial expected by mid-2024, delayed due to slower patient enrollment.
RAPT Therapeutics, a clinical-stage biopharmaceutical company focused on immunology, will have CEO Brian Wong participate in a fireside chat at the SVB Securities Global Biopharma Conference on February 14, 2023, at 1:40 p.m. ET. The event will discuss RAPT's efforts in developing oral small molecule therapies for inflammatory diseases and oncology, including their drug candidates RPT193 and FLX475, aimed at targeting C-C motif chemokine receptor 4 (CCR4). Investors and interested parties can access the live webcast and archived recording on RAPT's website.
RAPT Therapeutics, a clinical-stage biopharmaceutical company, announced that its CEO, Brian Wong, will present at the 41st Annual J.P. Morgan Healthcare Conference on January 10, 2023, at 3:00 p.m. PT. The conference provides a platform for companies to discuss innovations in healthcare. RAPT focuses on developing oral small molecule therapies for inflammatory diseases and oncology. Their notable drug candidates include RPT193 and FLX475, targeting CCR4 receptors. A live webcast of the presentation will be available on their official website.
RAPT Therapeutics presented promising data at the ESMO Immuno-Oncology Congress for its ongoing Phase 1/2 trial of FLX475, showing a confirmed overall response rate of 31% in checkpoint-naïve NSCLC patients, with ongoing responses exceeding one year. Among 13 patients, 38% of those with PD-L1 positive tumors responded, while 25% responded in the PD-L1 negative group. Additionally, a separate cohort of patients with EBV+ NK/T cell lymphoma displayed four responses, including two durable complete metabolic responses. The safety profile of FLX475 remained favorable.